OTC genetic-testing developer 23andMe, Inc. will become a publicly traded US company through a merger with an investment group backed by Virgin Group founder Sir Richard Branson in a deal that values the company at $3.5bn, including debt.
As part of the agreement with the VG Acquisition Corp., which is Virgin's special purpose acquisitions company (SPAC), 23andMe will receive proceeds of $759m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?